CQP(SZ:000950) Zheng Quan Shi Bao Wang·2025-10-27 16:13Core Insights - The company reported a revenue of 62.211 billion yuan for the first three quarters of the year, representing a year-on-year growth of 4.22% [2] - The net profit attributable to shareholders reached 384 million yuan, showing a significant increase of 31.41% year-on-year [2] - The company achieved a net profit of 102 million yuan in the third quarter alone, with a remarkable year-on-year growth of 87.94% [2] Financial Performance - For the first three quarters, the company’s net profit after deducting non-recurring gains and losses was 379 million yuan, up 36.83% year-on-year [2] - Earnings per share for the first three quarters stood at 0.22 yuan, reflecting a year-on-year increase of 29.41% [2] - In the third quarter, the company’s revenue was 21.023 billion yuan, marking a 5.57% increase compared to the same period last year [2] Business Development - The company’s various segments, including pharmaceuticals, medical devices, traditional Chinese medicine, specialty pharmacies, and emerging businesses, all demonstrated steady growth [2] - The company is optimizing its business network layout, enhancing market penetration and comprehensive service capabilities, which supports steady revenue growth [2] Operational Efficiency - The company has deepened its refined management practices through process optimization, resource integration, and digital upgrades, leading to improved operational efficiency [2] - Cost control capabilities have been strengthened, effectively reducing operating expenses and achieving cost reduction and efficiency enhancement [2] - The improvement in management efficiency has provided strong support for the continuous enhancement of profitability and rapid increase in net profit [2]